编者按：2024年美国临床肿瘤学会胃肠道肿瘤研讨会（2024 ASCO Gastrointestinal Cancers Symposium，ASCO GI 2024）将于美国当地时间2024年1月18～20日在旧金山召开。近日ASCO GI官网披露了摘要标题，现整理将于1月20日登场的中国结直肠肿瘤研究，以飨读者。排名不分先后，如有遗漏或错误，欢迎广大读者朋友提醒及指正。
01
口头报告专场
Effect of laparoscopy-assisted vs open surgery on 3-year disease-free survival in patients with low rectal cancer: The LASRE randomized clinical trial.
腹腔镜辅助手术与开放手术对低位直肠癌患者3年无病生存率的影响:LASRE随机临床试验
Presenter: 池畔（福建医科大学附属协和医院）
Abstract: 8
02
壁报专场
Trials in Progress Poster Session Level 1, West HallTrials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
A randomized controlled trial of CAPEOX vs observation in patients with early-stage colorectal cancer with positive MRD after curative surgery (CAREME).
一项随机对照试验CAPEOX vs观察早期结直肠癌治愈性手术后MRD阳性患者(CAREME)
Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab for locally advanced MSS of middle and low rectal cancer (mRCAT): An open-label, single-arm, prospective, multicentre clinical trial.
保留淋巴结改良短程放疗联合CAPOX和替雷利珠单抗治疗局部晚期MSS 中、低位直肠癌(mRCAT):一项开放标签、单臂、前瞻性、多中心临床试验
| Poster Bd #: P1
Artificial intelligence-based model for recurrence prediction after local excision on whole slide images in T1 low rectal cancer.
基于人工智能的T1低位直肠癌完整图像局部切除后复发预测模型
Use of micronuclei DNA from erythrocytes in early-stage colorectal cancer detection.
红细胞微核DNA在早期结直肠癌检测中的应用
Presenter: Xingyun Yao（西湖大学）
Abstract: 25
| Poster Bd #: C6
Fruquintinib with PD-1 inhibitors versus TAS-102 with bevacizumab in late-line mCRC: A retrospective cohort study based on propensity score matching.
呋喹替尼联合PD-1抑制剂与TAS-102联合贝伐珠单抗后线治疗晚期mCRC:一项基于倾向评分匹配的回顾性队列研究
Presenter: 李蓉蓉（湖南省肿瘤医院）
Abstract: 95
| Poster Bd #: F18
Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
larorectinib (laro)在TRK融合胃肠道(GI)癌患者中的最新疗效和安全性
Presenter:沈琳（北京大学肿瘤医院）
Abstract: 109
| Poster Bd #: G13
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.
安罗替尼联合化疗作为胃肠道肿瘤伴不可切除肝转移患者的一线治疗:来自多队列、多中心II期试验ALTER-G-001-cohort A的最新结果
Presenter: 吴珺玮（上海交通大学医学院附属瑞金医院）
Abstract: 112
| Poster Bd #: G16
Initial efficacy evaluation of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer (mCRC): A randomized, controlled, phase Ib/II study.
氟喹替尼加卡培他滨与卡培他滨作为转移性结直肠癌(mCRC)维持治疗的初步疗效评估:一项随机、对照、Ib/II期研究
Presenter: 李文桦（复旦大学附属肿瘤医院）
Abstract: 119
| Poster Bd #: H4
Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy.
曲氟尿苷替匹嘧啶(TAS-102)联合抗EGFR与TAS-102 +抗VEGF在一线抗EGFR基石化疗的mCRC患者中的再挑战应用
Presenter: Ching Tso Chen（中国国立台湾大学）
Abstract: 120
| Poster Bd #: H5
First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
转移性结直肠癌的一线serpluliumab + HLX04和XELOX vs安慰剂+贝伐珠单抗和XELOX:一项2/3期研究
Presenter: 徐瑞华（中山大学肿瘤防治中心）
Abstract: 124
| Poster Bd #: H9
Regorafenib plus FOLFIRI with irinotecan dose escalated according to UGT1A1 genotyping in patients with metastatic colorectal cancer.
根据UGT1A1基因分型，转移性结直肠癌患者瑞戈非尼+ FOLFIRI +伊立替康剂量递增试验
Presenter: Chao-Yuan Wang（中国台湾高雄医学大学）
Abstract: 125
| Poster Bd #: H10
Preliminary efficacy and safety of fruquintinib as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, randomized, open-label clinical trial (the FRONT study).
转移性结直肠癌(mCRC)一线治疗后呋喹替尼维持治疗的初步疗效和安全性:一项多中心、随机、开放标签临床试验(FRONT研究)
Presenter: 刘天舒（复旦大学附属中山医院）
Abstract: 126
| Poster Bd #: H11
Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
ALTER-C002的最新生存结果:安罗替尼联合CAPEOX作为RAS/BRAF野生型不可切除转移性结直肠癌的一线治疗
Presenter: 刘月（浙江大学医学院附属第二医院）
Abstract: 131
| Poster Bd #: H16
Fruquintinib with PD-1 inhibitors versus fruquintinib monotherapy in late-line mCRC: A retrospective cohort study based on propensity score matching.
呋喹替尼联合PD-1抑制剂与呋喹替尼单药后线治疗mCRC:一项基于倾向评分匹配的回顾性队列研究
Presenter: Tianqi An（郑州大学一附属医院）
Abstract: 139
| Poster Bd #: J5
Results of a prospective phase II study of total neoadjuvant therapy for locally advanced rectal cancer.
局部晚期直肠癌全程新辅助治疗的前瞻性II期研究结果
Presenter: Huiying Ma（中国医学科学院肿瘤医院）
Abstract: 147
| Poster Bd #: J13
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?
结直肠癌配对活检和手术标本中微卫星不稳定性(MSI)状态的一致性和异质性:治疗后重新评估MSI的必要性?
Presenter: 唐源（四川大学华西医院）
Abstract: 149
| Poster Bd #: J15
Comprehensive genomic analysis of molecular residual disease based on circulating tumor DNA in patients with postoperative colorectal cancer.
基于循环肿瘤DNA的结直肠癌术后患者分子残留病的综合基因组分析
Presenter: 洪清琦（厦门大学附属第一医院）
Abstract: 156
| Poster Bd #: K4
The mechanistic study of cancer-associated adipocytes promoting colorectal cancer peritoneal metastasis via FKBP5/UCP1-mediated lipid metabolism reprogramming.
肿瘤相关脂肪细胞通过FKBP5/ ucp1介导的脂质代谢重编程促进结直肠癌腹膜转移的机制研究
Presenter: 张玥（南方医科大学南方医院）
Abstract: 178
| Poster Bd #: L6
Incidence and genomic characteristics of gene fusions in a large Chinese colorectal cancer cohort.
中国大型结直肠癌队列中基因融合的发生率和基因组特征
Presenter: 寇芙蓉（北京大学肿瘤医院）
Abstract: 192
| Poster Bd #: L20